Quantification of HER family receptors in breast cancer

Abstract : The clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification of patients eligible for targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH) assays are routinely used to select patients to receive trastuzumab, both assays only partially predict response to the drug. In the case of epidermal growth factor receptor (EGFR), the link between the presence of the receptor or its amplification and response to anti-EGFR therapies could not be demonstrated. Even less is known for HER3 and HER4, mainly due to lack of robust and validated assays detecting these proteins. It is becoming evident that, besides FISH and IHC, we need better assays to quantify HER receptors and categorize the patients for individualized treatments. Here, we present the current available methodologies to measure HER family receptors and discuss the clinical implications of target quantification.
Document type :
Journal articles
Complete list of metadatas

Cited literature [157 references]  Display  Hide  Download

https://hal.uca.fr/hal-02387771
Contributor : Nina Radosevic-Robin <>
Submitted on : Saturday, November 30, 2019 - 11:17:43 AM
Last modification on : Wednesday, December 4, 2019 - 1:25:22 AM

File

011 Quantification of HERs i...
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Collections

Citation

Paolo Nuciforo, Nina Radosevic-Robin, Tony Ng, Maurizio Scaltriti. Quantification of HER family receptors in breast cancer. Breast Cancer Research, BioMed Central, 2015, ⟨10.1186/s13058-015-0561-8⟩. ⟨hal-02387771⟩

Share

Metrics

Record views

24

Files downloads

29